Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASLN ASLAN Pharmaceuticals	$0.60	$0.60	$0.48 ▼ $25.44	$1.23M	1.4	122,322 shs	N/A
EVFM Evofem Biosciences	$0.01	$0.01	$0.01 ▼ $0.02	$1.19M	-0.99	413,165 shs	300,879 shs
KRBP Kiromic BioPharma		$1.16	$0.16 ▼ $3.32	$330K	1.66	11,347 shs	107,749 shs
VCNX Vaccinex	$0.45 -2.2%	$0.76	$0.25 ▼ $1.40	$1.17M	1.1	2,986 shs	272 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASLN ASLAN Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	0.00%	+3.09%	+4.17%	0.00%	+1.01%
KRBP Kiromic BioPharma	0.00%	0.00%	0.00%	0.00%	-89.12%
VCNX Vaccinex	0.00%	-12.70%	-35.70%	-51.33%	-91.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	1.8972 of 5 stars	0.0	5.0	0.0	4.8	3.1	0.0	0.0
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	0.4334 of 5 stars	0.0	4.0	0.0	0.0	0.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASLN ASLAN Pharmaceuticals	$12M	0.10	N/A	N/A	($6.50) per share	-0.09
EVFM Evofem Biosciences	$11.39M	0.10	N/A	N/A	($2.64) per share	0.00
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	($8.29) per share	N/A
VCNX Vaccinex	$388K	3.02	N/A	N/A	($2.59) per share	-0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASLN ASLAN Pharmaceuticals	-$44.22M	-$21.92	N/A	∞	N/A	N/A	-8,454.87%	-121.60%	N/A
EVFM Evofem Biosciences	$52.98M	-$0.07	N/A	∞	N/A	-46.42%	-91.97%	-61.93%	N/A
KRBP Kiromic BioPharma	-$26.90M	-$3.50	N/A	N/A	N/A	N/A	N/A	-277.46%	N/A
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	11/12/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASLN ASLAN Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
KRBP Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASLN ASLAN Pharmaceuticals	N/A	1.05	1.05
EVFM Evofem Biosciences	N/A	0.11	0.09
KRBP Kiromic BioPharma	N/A	0.16	0.22
VCNX Vaccinex	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASLN ASLAN Pharmaceuticals	58.82%
EVFM Evofem Biosciences	0.22%
KRBP Kiromic BioPharma	10.91%
VCNX Vaccinex	50.11%

Insider Ownership

Company	Insider Ownership
ASLN ASLAN Pharmaceuticals	4.69%
EVFM Evofem Biosciences	0.01%
KRBP Kiromic BioPharma	20.59%
VCNX Vaccinex	51.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASLN ASLAN Pharmaceuticals	30	2.04 million	1.95 million	Optionable
EVFM Evofem Biosciences	120	118.66 million	113.12 million	Not Optionable
KRBP Kiromic BioPharma	60	1.57 million	1.22 million	Not Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data

KRBP, ASLN, VCNX, and EVFM Headlines

Recent News About These Companies

Vaccinex presents promising cancer treatment data at ASCO

May 29, 2025 | uk.investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025

May 29, 2025 | nasdaq.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025 | globenewswire.com

AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finanznachrichten.de

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finance.yahoo.com

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

April 22, 2025 | markets.businessinsider.com

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025

April 21, 2025 | quiverquant.comQ

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025 | globenewswire.com

Vaccinex director resigns, no disagreement cited

March 21, 2025 | investing.com

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

March 10, 2025 | finance.yahoo.com

Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 8, 2025 | finanznachrichten.de

Vaccinex to delist common stock from Nasdaq

March 7, 2025 | markets.businessinsider.com

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025 | globenewswire.com

Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Vaccinex receives delisting notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Shares Tumble 63% On Nasdaq Delisting

December 17, 2024 | marketwatch.com

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

December 17, 2024 | finance.yahoo.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

December 17, 2024 | benzinga.com

Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

December 17, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

KRBP, ASLN, VCNX, and EVFM Company Descriptions

ASLAN Pharmaceuticals NASDAQ:ASLN

$0.60 0.00 (0.00%)

As of 08/27/2025

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Evofem Biosciences NASDAQ:EVFM

$0.01 0.00 (0.00%)

As of 08/28/2025 03:53 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Kiromic BioPharma NASDAQ:KRBP

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Vaccinex NASDAQ:VCNX

$0.45 -0.01 (-2.15%)

As of 08/27/2025 10:36 AM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time